Patient Safety: Drug Induced Cardiovascular Disease

C. Michael White, Pharm.D., FCP, FCCP Distinguished Professor and Chair, Pharmacy Practice

UConn School of Pharmacy

Disclosures:

4

• Dr White has received no funding from any company that makes Dr White has received no funding from any company that makes any of the drugs covered in this presentation and is not an individual stock owner for any of the companies either. He does not have any financial or nonfinancial conflicts of interest germane to this presentation. In addition, he will be discussing drug adverse events which are aligned with those already denoted in the drugs package inserts, albeit in much greter depth. He will not be talking about investigational drugs or the off-label use of

1 2

Objectives


At the conclusion of this lecture the successful learner will be able to:


- Identify heart block
- \bullet Differentiate between 1st, type-1 $2^{nd},$ type-2 $2^{nd},$ and 3^{rd} degree AV block
- Describe the drugs and dietary supplements that can cause heart block and what to do if drug induced heart block occurs acutely and chronically
- Identify QTc interval prolongation and describe how much of an elevation dramatically enhances the risk of Torsade de Pointes
- Describe drugs and dietary supplements that may prolong QTc interval and interventions for acute Torsade de Pointes or chronic QTc interval prolongation
- Apply knowledge to a patient relevant case

This entire lecture is based on the following book chapter:
White CM, Kalus J. Cardiac Arrhythmias, Chapter 20. In: Alldredge BK, Corelli RL,
Ernst ME (Eds.), Applied Therapeutics: The Clinical Use of Drugs. 11th Edition.
Lippincott Williams & Wilkins, NY, NY. 2021 pg. 20.1-20.35.


Electrical System of the Heart


3





5 6






Drugs That Induce Heart Block: (Red Box = Gotta Know)			
Anti-Hypertensive/Anti- Anginal	Anti-Arrhythmic	Psychoactive	Other
Beta-Blockers: Metoprolol, Propranolol, Atenolol, etc	Class Ia AAs: Quinidine, Procainamide	Opioids	Propofol
Non-DHP-CCBs: Verapamil, Diltiazem	Class Ib AAs: Lidocaine, Mexelitine	Donepazil	Succinylcholine
Clonidine	Class Ic AAs: Flecainide & Propafenone	Phenothiazines: Chlorpromazine, etc	Cannabis
Methyldopa	Class III AAs: Amiodarone, Dronedarone, Sotalol	Phenytoin	
Ivabridine	Digoxin, Natural Cardiac Glycosides	SSRIs: fluoxetine, sertraline, etc	
	Adenosine	Tricyclics: amitriptyline, etc	

Acutely Managing Heart Block Hold offending agent(s) - If symptoms mild (slight dizziness) and PR>200ms, or no symptoms but PR >240ms · Watchful waiting · If symptom moderate/severe Atropine 0.5 to 2mg IV Isoproterenol infusion Transvenous temporary pacing • If major overdose - activated charcoal, consider dialysis · Glucagon 3-10mg IV

9 10

What Do You Do After Heart Block? • Once heart block resolves (PR < 200ms, symptoms resolved): • Is drug really needed, are their equally good alternatives?
• Yes - use alternative [IF THE ANSWER IS NO]... · If due to gross overdose - is risk of new overdose low? Yes - restart; No - Stop
 If due to inappropriate dose for age, renal function, hepatic function
 Can a lower dose or drug in same class with different clearance pathway be used?
 Yes - restart; No - Stop If due to drug interaction - can interaction be avoided?
 Yes - restart one of the offending agents; No - use lower doses and monitor more closely Pharmacokinetic/Dynamic Drug Interactions Metoprolol, Propranolol, Carvedilol Quinidine, ritonavir, SSRIs (fluoxetine, paroxetine, sertraline), duloxetine, buproprion, CBD, cinacalcet, amiodarone, CYP2D6 All other PR interval prolonging drugs Renal Dysfunction Nadolol CYP3A4 Ketoconazole, itraconazole, HIV protease Verapamil inhibitors, cyclosporin, grapefruit juice, erythromycin, clarithromycin, nefazodone, amiodarone, dronedarone [For digoxin, drugs that lower potassium (loop diuretics, thiazide Diltiazem Multiple CYP's Ouinidine (due to kinetic and dynamic) diuretics) increase risk of digoxin toxicity including heart block] P-Glycoprotein Quinidine, amiodarone, flecainide, Digoxin propafenone, verapamil

12 11



Torsade de Pointes (TdP) · A polymorphic ventricular tachycardia • Can be caused by R-on-T phenomenon (depolarization in vulnerable repolarization state) White CM. Pharmacotherapy. 1999;19:635-640.

14

Torsade de Pointes

- Polymorphic Ventricular Tachycardia
 Caused by QTc interval prolongation >500ms (0.5 sec)
 Or increased >60 ms from baseline
 - Caution with Class Ia or III agents if baseline QTc interval is >440ms
 - Caution with non-AA agents that prolong QTc interval (antipsychotics, flouroquinolones, macrolides, select opioids [methadone, kratom, oliceridine, loperamide]) if baseline QTc interval -470ms

 Female gender has higher QTc interval than men (13 msec higher)

 Hypokalemia, hypomagnesemia increases QTc interval

 - Class la and III agents except amiodarone have greater QTc interval prolongation when heart rate slower (reverse use dependence)

Acute Treatment of TdP

- Hemodynamically stable:
 - IV magnesium is drug of choice (2g bolus then 1g/hour for 18 hours)
 - Lidocaine is second line therapy (see lidocaine)
- Hemodynamically unstable (unconscious, can't mentate, causing myocardial ischemia)
 - · Electrically shock right away

16 15

What Do You Do After TdP or Severe QTc Interval Prolongation?

- Once QTc interval resolves (< 440ms or less than 30ms increase from baseline, symptoms resolved):
 - · Is drug really needed, are their equally good alternatives?

Yes - use alternative
[IF THE ANSWER IS NO]...

- If due to gross overdose is risk of new overdose low?
- Yes restart; No Stop
 If due to inappropriate dose for age, renal function, hepatic function
 - · Can a lower dose or drug in same class with different clearance pathway be used? • Yes - restart; No - Stop
- If due to drug interaction can interaction be avoided?
 - Yes restart one of the offending agents; No use lower doses and monitor more closely

Pharmacokinetic/Dynamic Drug Interactions Ouinidine CYP3A4 Ketoconazole, itraconazole, HIV protease All other QTc Prolonging drugs in column A + macrolides, antipsychotics, tricyclic antidepressants, flouroquinolones, prothodone, kratom inhibitors, cyclosporin, grapefruit juice, erythromycin, clarithromycin, nefazodone Procainamide Cation tubular Ketoconazole, megestrol, cimetidine, hydrochlorothiazide, prochlorperazine, trimethoprim secretion inhibitors Sotalol Renal Renal dysfunction methadone, kratom, Ketoconazole, megestrol, cimetidine, hydrochlorothiazide, prochlorperazine, trimethoprim Dofetilide Cation tubular loperamide (mega-dose), secretion inhibitors Amindarone CYP3A4 (minor) Ketoconazole, itraconazole, hiv protease inhibitors, cyclosporin, grapefruit juice, erythromycin, clarithromycin, nefazodone Ketoconazole, itraconazole, HIV protease inhibitors, cyclosporin, grapefruit juice, erythromycin, clarithromycin, nefazodone CYP3A4 (minor) biliary excretion

17 18

Conclusions

- Pharmacists need to use proper dosing and avoid drug interactions that can increase the risk of drug-induced disease
- Pharmacists need to look specifically for evidence of drug induced disease
 Catch them early before severe toxicity results
- Pharmacists need to identify potential acute treatments and suggest whether and how to restart the drugs after the acute issues have passed